Cite
HARVARD Citation
Hochberg, M. et al. (2016). When Is Osteonecrosis Not Osteonecrosis?: Adjudication of Reported Serious Adverse Joint Events in the Tanezumab Clinical Development Program. Arthritis & rheumatology. 68 (2), pp. 382-391. [Online].